Overcoming Challenges with Transpara
In addition to extensive clinical research published in peer reviewed journals, we are always excited to share insights gathered along the path of rigorous scientific study and clinical practice.
Groundbreaking Randomized MASAI Trial Demonstrates Transpara plays a vital role in improving early detection, leading to better outcomes and more efficient use of radiologist time
Research Published in Radiology Shows that Combination of Transpara-based Lesion Detection, Volumetric Density and Quantitative Texture Analysis Delivers Improved Breast Cancer Risk Prediction NIJMEGEN, The
Nijmegen, The Netherlands, November 12, 2024 – In a powerful front-page story in De Telegraaf, Karin Boxem, 56, from Giesbeek, the Netherlands, reflects on how
© 2023, ScreenPoint Medical BV. All rights reserved. Transpara® is a registered trademark of ScreenPoint Medical BV. Reproduction of any material contained herein in any format or media without express written permission of ScreenPoint Medical BV is prohibited. *Disclaimer: Transpara is CE marked and FDA cleared for 2D and 3D mammography. CE (0344) certified. FDA 510(k) K210404. Not all features are available in all countries. Please check with local representatives.
Lake Medical Imaging Case Study
Download the study to see how Transpara reduces radiologist workload and improves diagnostic confidence.
